香港股市 將在 8 分鐘 開市
  • 恒指

    17,222.83
    0.00 (0.00%)
     
  • 國指

    5,914.08
    0.00 (0.00%)
     
  • 上證綜指

    3,024.39
    -16.81 (-0.55%)
     
  • 道指

    28,725.51
    -500.09 (-1.71%)
     
  • 標普 500

    3,585.62
    -54.85 (-1.51%)
     
  • 納指

    10,575.62
    -161.88 (-1.51%)
     
  • Vix指數

    31.62
    -0.22 (-0.69%)
     
  • 富時100

    6,893.81
    +12.22 (+0.18%)
     
  • 紐約期油

    81.55
    +2.06 (+2.59%)
     
  • 金價

    1,673.80
    +1.80 (+0.11%)
     
  • 美元

    7.8495
    -0.0003 (-0.00%)
     
  • 人民幣

    0.9062
    +0.0005 (+0.06%)
     
  • 日圓

    0.0541
    +0.0001 (+0.17%)
     
  • 歐元

    7.7005
    +0.0066 (+0.09%)
     
  • Bitcoin

    19,179.84
    -115.05 (-0.60%)
     
  • CMC Crypto 200

    435.61
    -7.82 (-1.76%)
     

Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate

·1 分鐘文章

Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets.

  • Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for all three target pathogens.

  • For PfAPP, Zymergen has already identified over 200 molecules with better docking scores than the current molecule, apstatin.

  • Docking scores are well-accepted in the industry for virtual screening campaigns, and the best hits are now being moved into validation testing with global partners.

  • Zymergen will oversee all validation.

  • Price Action: ZY shares closed 0.62% higher at $3.25 during after-hours trading on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.